Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) has appointed Darius Adamczyk, Chairman and CEO of Honeywell, to its Board of Directors, effective February 15, 2022. Adamczyk is recognized for his extensive business leadership and commitment to sustainability and innovation. His appointment is expected to enhance the board's diverse expertise and support JNJ's focus on creating healthier communities and delivering transformative health solutions. Adamczyk expressed his honor to join JNJ at a crucial time, emphasizing the company's values-driven mission to improve lives and create long-term stakeholder value.
Johnson & Johnson (NYSE: JNJ) will attend the Raymond James 43rd Annual Institutional Investors Conference on March 8, 2022. Joseph J. Wolk, Executive Vice President and CFO, will speak at 1:05 p.m. ET. Investors can view the session via a webcast on their official website, www.investor.jnj.com. A replay will be accessible approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on March 7, 2022, at 9:10 a.m. (Eastern Time). Mathai Mammen, Executive VP of Pharmaceuticals R&D, will represent the company. Investors and interested parties can access the conference call via the Johnson & Johnson website. A webcast and podcast replay will be available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on February 23, 2022. The session will feature Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, presenting at 11:00 a.m. ET. Interested investors can access the conference via the Johnson & Johnson website. Following the live event, a webcast and podcast replay will be available approximately 48 hours later.
Johnson & Johnson (NYSE: JNJ) reported a robust performance for Q4 and full-year 2021. Reported sales reached $24.8 billion in Q4, a 10.4% increase, and $93.8 billion for the year, up 13.6%. Net earnings surged by 172.5% in Q4 to $4.7 billion, while full-year net earnings rose 41.9% to $20.9 billion. Adjusted operational sales growth was notable in Pharmaceuticals (13.6%) and Medical Devices (16.8%), despite supply constraints in Consumer Health. New product approvals and a planned separation of the Consumer Health business were also highlighted as key strategic moves for future growth.
On January 6, 2022, Johnson & Johnson (NYSE: JNJ) released findings from the largest study on COVID-19 vaccine durability in the U.S., highlighting that a single dose of their vaccine provides long-term protection for up to six months. The study, conducted with leading institutions, confirmed an approximately 80% effectiveness against hospitalizations. Notable results included no waning protection against ICU admissions and a modest increase in breakthrough infections after month four. This research positions the Johnson & Johnson vaccine as a viable option amid evolving COVID-19 variants.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the first quarter of 2022. This dividend payment is scheduled for March 8, 2022, to shareholders on record as of February 22, 2022, with an ex-dividend date of February 18, 2022. The announcement underscores the company's commitment to returning value to its shareholders while continuing its mission to improve health outcomes globally.
Johnson & Johnson (NYSE: JNJ) reported positive preliminary results from the South African Phase 3b Sisonke study, indicating an 85% effectiveness of its COVID-19 vaccine booster against hospitalization during the Omicron variant surge. The study involved healthcare workers and revealed that vaccine effectiveness increased over time post-boost. Additionally, a separate analysis showed that a heterologous booster regimen significantly enhanced immune responses compared to a homologous booster. These findings underscore the robustness of the Johnson & Johnson vaccine amidst evolving COVID-19 variants.
The CHMP of the EMA issued a Positive Opinion for Johnson & Johnson's COVID-19 vaccine booster, recommending it for adults 18+ at least two months post-initial vaccination. The booster increased protection to 75% against symptomatic COVID-19 and demonstrated 100% protection against severe cases, with data from the Phase 3 ENSEMBLE 2 study. The vaccine was generally well-tolerated, showing no new safety concerns. The recommendation supports its use as a 'mix and match' booster.
Johnson & Johnson (NYSE: JNJ) will hold a conference call on January 25, 2022, at 8:30 a.m. Eastern Time to discuss its fourth-quarter results. The call will feature key executives, including Joaquin Duato, the incoming CEO. Investors can access the call via the company's website and by phone. A replay will be available until February 8, 2022. The earnings report will be released at approximately 6:45 a.m. Eastern Time on the same day. For future events, please visit Johnson & Johnson's investor relations page.